RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).

Hogner, A; Breithaupt, K; Stein, A; Hinke, A; Lorenz, M; Al-Batran, SE; Thuss-Patience, PC

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索